The study demonstrated that β-catenin signaling (CTNNB1) mediated immune escape of tumors by preventing recruitment of CD103+ DCs leading to an early failure of the cancer immune cycle that inhibited generation of robust tumor-specific T cell activity. Here, CTNNB1 is linked to neoplasm.